Brief: Theranexus And BBDF Announce Agreement In Principle To Develop And Market Batten Disease Drug Candidate
27/06/2019 17:29
June 27 (Reuters) - THERANEXUS SA ALTHX.PA :
* THERANEXUS AND BEYOND BATTEN DISEASE FOUNDATION (BBDF)
ANNOUNCE
AGREEMENT IN PRINCIPLE TO DEVELOP AND MARKET BATTEN DISEASE DRUG
CANDIDATE BBDF 101
* BBDF HAS FUNDED RESEARCH TO IDENTIFY AND VALIDATE BBDF 101
FOR
THE TREATMENT OF JUVENILE BATTEN DISEASE
* THERANEXUS AND BBDF WILL JOINTLY LEAD THE CLINICAL
DEVELOPMENT
PROGRAM IN THE US TO SECURE REGULATORY APPROVAL FOR THE PRODUCT
* THERANEXUS WILL HAVE AN EXCLUSIVE WORLDWIDE LICENSE FOR
COMMERCIAL USE OF THE PRODUCT
Source text for Eikon: ID:nACT59021
Further company coverage: ALTHX.PA
(Gdynia Newsroom)
((gdynia.newsroom@thomsonreuters.com; +48 58 772 0920;))
Recent news on Thx Pharma SA
See all newsBrief: Theranexus And BBDF Announce Final And Positive Safety And Efficacy Data In The Phase I/II Trial Testing Batten-1
Brief: Theranexus End-Dec Total Available Funds Stood At EUR 4.9 Mln
Brief: Theranexus Declares Encouraging Prelim Results For Batten Disease Drug
Brief: Theranexus And BBDF Granted Positive Opinion By EMA For Design Of Batten-1 Phase III Trial
Brief: Theranexus And BBDF Win FDA Approval On Endpoints For Phase III Trial To Evaluate Batten-1 In CLN3 Batten Disease